Last Updated : April 4, 2025
Details
FilesGeneric Name:
fruquintinib
Project Status:
Complete
Therapeutic Area:
Metastatic colorectal cancer (mCRC)
Manufacturer:
Takeda Canada Inc.
Call for patient/clinician input open:
Brand Name:
Fruzaqla
Project Line:
Reimbursement Review
Project Number:
PC0352-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, an anti-EGFR agent (if RAS wild-type), and either trifluridine-tipiracil or regorafenib.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, an anti-EGFR agent (if RAS wild-type), and either trifluridine-tipiracil or regorafenib.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation/Report:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | March 28, 2024 |
|---|---|
| Call for patient/clinician input closed | May 21, 2024 |
| Submission received | May 22, 2024 |
| Submission accepted | June 05, 2024 |
| Review initiated | June 06, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | August 21, 2024 |
| Deadline for sponsors comments | August 30, 2024 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | September 26, 2024 |
| Expert committee meeting (initial) | October 09, 2024 |
| Draft recommendation issued to sponsor | October 22, 2024 |
| Draft recommendation posted for stakeholder feedback | October 31, 2024 |
| End of feedback period | November 15, 2024 |
| Final recommendation issued to sponsor and drug plans | November 27, 2024 |
| Final recommendation posted | December 13, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | December 11, 2024 |
| CDA-AMC review report(s) posted | April 04, 2025 |
Files
Last Updated : April 4, 2025